NanoLogix Inc (NNLX)

[machiavelli10]

NanoLogix Establishes New "Gold Standard" for TB Testing

In the several days since USAToday published information on NanoLogix technology in association with a diagnostic breakthrough for Group B Strep testing in pregnant women there has been significant attention paid to the company and the implications of its technology. It is truly revolutionary for a variety of reasons I mentioned in an earlier posting of last week. But surprisingly little comment has been made relating to the scientific conclusions of the Battelle Institute's Dr. James Rogers, Manager of Bacteriology and In Vitro Operations at Battelle, and an expert at the cutting edge of technological developments in the field. For the analysis of Rogers and Dr. John Faro, see: http://sites.conversionplanet.com/group-b-strep-awareness/group%20b%20strep/how-rapid-testing-can-change-the-diagnosis-and-treatment-of-gbs.

Dr. Rogers provided a bold endorsement of the BNP diagnostic technology when he observed that BNP not only represented a breakthrough for Group B Strep, but: "The technology can also be used for other bacteria and may prove crucial in diagnosing tuberculosis (TB). Typical culture tests for TB currently take three to four weeks, while NanoLogix's test results take only five days or 1.5 hours, depending on which test is being used. Tuberculosis remains the second-leading infectious disease killer in the Americas (after HIV/AIDS) despite significant progress in controlling the disease, according to the Pan American Health Organization/World Health Organization (PAHO/WHO."

Rogers continued: "Tuberculosis is a global public health concern in which early diagnosis is critical to enabling health care providers the ability to provide the necessary medical treatment in a timely manner," ... [and added] "Although there have been advances in the available techniques to help diagnose M. tuberculosis infection, the [current] gold standard method for laboratory is culture on semi-solid media that can require up to three to four weeks. This study demonstrates that BNP™ Middlebrook can detect M. tuberculosis within 5 days, which is faster than the gold standard and provides a preliminary assessment of the potential use of BNP™ Middlebrook for a more rapid screening and detection of viable M. tuberculosis with respect to clinical specimen evaluation, therapeutic treatment/vaccine efficacy, or epidemiological surveillance,".

This means that the BNP is between four to six times faster than the current "gold standard" for TB diagnosis in the most difficult forms of assessment. It is not irrational to conclude that the gold goes to the new challenging technology that "wins the race" head-to-head. In the "race" to diagnose Group B Strep and Tuberculosis that is BNP. As Dr. Rogers indicates in his concluding sentence offered above, the significant advantage of BNP is not simply one of faster diagnosis but of "treatment, efficacy and surveillance". As described on the NanoLogix website there are important medical situations "when time matters".